CL2020000655A1 - Tratamiento mejorado de dermatitis atópica con tradipitant. - Google Patents
Tratamiento mejorado de dermatitis atópica con tradipitant.Info
- Publication number
- CL2020000655A1 CL2020000655A1 CL2020000655A CL2020000655A CL2020000655A1 CL 2020000655 A1 CL2020000655 A1 CL 2020000655A1 CL 2020000655 A CL2020000655 A CL 2020000655A CL 2020000655 A CL2020000655 A CL 2020000655A CL 2020000655 A1 CL2020000655 A1 CL 2020000655A1
- Authority
- CL
- Chile
- Prior art keywords
- tradipitant
- atopic dermatitis
- improved treatment
- treatment
- improved
- Prior art date
Links
- 206010012438 Dermatitis atopic Diseases 0.000 title abstract 2
- CAVRKWRKTNINFF-UHFFFAOYSA-N [2-[1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-pyridin-4-yltriazol-4-yl]pyridin-3-yl]-(2-chlorophenyl)methanone Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(CN2C(=C(N=N2)C=2C(=CC=CN=2)C(=O)C=2C(=CC=CC=2)Cl)C=2C=CN=CC=2)=C1 CAVRKWRKTNINFF-UHFFFAOYSA-N 0.000 title abstract 2
- 201000008937 atopic dermatitis Diseases 0.000 title abstract 2
- 229950011232 tradipitant Drugs 0.000 title abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Physical Education & Sports Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762558303P | 2017-09-13 | 2017-09-13 | |
| US201762572456P | 2017-10-14 | 2017-10-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2020000655A1 true CL2020000655A1 (es) | 2020-10-09 |
Family
ID=63684468
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2020000655A CL2020000655A1 (es) | 2017-09-13 | 2020-03-12 | Tratamiento mejorado de dermatitis atópica con tradipitant. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11549147B2 (https=) |
| EP (2) | EP4487912A3 (https=) |
| JP (1) | JP7347743B2 (https=) |
| KR (2) | KR20200054232A (https=) |
| CN (1) | CN111093671A (https=) |
| AU (1) | AU2018331267B2 (https=) |
| CA (1) | CA3073998A1 (https=) |
| CL (1) | CL2020000655A1 (https=) |
| IL (1) | IL272949B2 (https=) |
| MX (2) | MX2020002852A (https=) |
| WO (1) | WO2019055225A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2978736C (en) | 2015-03-04 | 2023-11-07 | Vanda Pharmaceuticals Inc. | Dosing regimen of tradipitant |
| CN112218636B (zh) | 2018-06-08 | 2025-05-06 | 万达制药公司 | 使用川地匹坦进行治疗的方法 |
| JP2023515167A (ja) * | 2020-02-25 | 2023-04-12 | バンダ・ファーマシューティカルズ・インコーポレイテッド | トラジピタントによるアトピー性皮膚炎の改善された治療 |
| WO2021195205A1 (en) | 2020-03-26 | 2021-09-30 | Vanda Pharmaceuticals Inc. | Treatment of lower respiratory tract infection with tradipitant |
| PL3996169T3 (pl) | 2020-05-07 | 2025-05-12 | Lg Energy Solution, Ltd. | Wysokoniklowy arkusz elektrody i sposób jego wytwarzania |
| US20240350469A1 (en) | 2021-08-31 | 2024-10-24 | Vanda Pharmaceuticals Inc. | Treatment of lower respiratory tract infection with tradipitant |
| CN120641099A (zh) | 2022-12-21 | 2025-09-12 | 万达制药公司 | 使用曲地匹坦的治疗方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW263498B (https=) | 1993-11-10 | 1995-11-21 | Takeda Pharm Industry Co Ltd | |
| KR100755577B1 (ko) | 2002-04-26 | 2007-09-12 | 일라이 릴리 앤드 캄파니 | 타키키닌 수용체 길항제로서의 트리아졸 유도체 |
| BR0309486A (pt) | 2002-04-26 | 2005-02-09 | Lilly Co Eli | Composto ou um seu sal farmaceuticamente aceitável, composição farmacêutica, e, método para o tratamento de uma condição associada com um excesso de taquicininas |
| JP2004250329A (ja) | 2002-12-26 | 2004-09-09 | Dainippon Pharmaceut Co Ltd | イサチン誘導体 |
| US7135575B2 (en) | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| NZ580480A (en) | 2003-10-24 | 2010-02-26 | Lilly Co Eli | Novel crystalline forms of {2-[1-(3,5-bis-trifluoromethylbenzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone |
| JP4673068B2 (ja) | 2005-01-19 | 2011-04-20 | 独立行政法人科学技術振興機構 | Ｔｈ１型アレルギー疾患治療用組成物 |
| DE102005006217B4 (de) | 2005-02-07 | 2007-08-16 | Universitätsklinikum Hamburg-Eppendorf | Diagnose von allergischen Erkrankungen und/oder atopischen Erkrankungen durch Nachweis von Autoantikörpern gegen CD28 in humanem Serum |
| WO2007096782A2 (en) | 2006-02-22 | 2007-08-30 | Valorisation Recherche Hscm, Limited Partnership | Compositions for disorders associated wtth metachromatic cell activation |
| CN101568523A (zh) | 2006-12-20 | 2009-10-28 | 伊莱利利公司 | 用于制备{2-[1-(3,5-二-三氟甲基-苄基)-5-吡啶-4-基-1h-[1,2,3]三唑-4-基]－吡啶－3－基｝·(2－氯苯基)甲酮的新中间体和方法 |
| JP6644328B2 (ja) | 2013-02-28 | 2020-02-12 | ロート製薬株式会社 | アトピー性疾患の発症又は重症化リスクの評価法 |
| US8906951B1 (en) | 2013-06-24 | 2014-12-09 | Tigercat Pharma, Inc. | Use of NK-1 receptor antagonists in pruritus |
| BR112015031724A2 (pt) | 2013-06-24 | 2017-07-25 | Tigercat Pharma Inc | uso do antagonista do receptor nk-1 serlopitant em pruridos |
| CA2978736C (en) | 2015-03-04 | 2023-11-07 | Vanda Pharmaceuticals Inc. | Dosing regimen of tradipitant |
| US10821099B2 (en) | 2018-09-28 | 2020-11-03 | Vanda Pharmaceuticals Inc. | Use of tradipitant in motion sickness |
-
2018
- 2018-08-30 CA CA3073998A patent/CA3073998A1/en active Pending
- 2018-08-30 CN CN201880059276.3A patent/CN111093671A/zh active Pending
- 2018-08-30 AU AU2018331267A patent/AU2018331267B2/en active Active
- 2018-08-30 US US16/644,567 patent/US11549147B2/en active Active
- 2018-08-30 WO PCT/US2018/048825 patent/WO2019055225A1/en not_active Ceased
- 2018-08-30 JP JP2020515146A patent/JP7347743B2/ja active Active
- 2018-08-30 MX MX2020002852A patent/MX2020002852A/es unknown
- 2018-08-30 IL IL272949A patent/IL272949B2/en unknown
- 2018-08-30 KR KR1020207010029A patent/KR20200054232A/ko not_active Ceased
- 2018-08-30 EP EP24211922.0A patent/EP4487912A3/en active Pending
- 2018-08-30 KR KR1020257006413A patent/KR20250036264A/ko active Pending
- 2018-08-30 EP EP18778635.5A patent/EP3681505B1/en active Active
-
2020
- 2020-03-12 CL CL2020000655A patent/CL2020000655A1/es unknown
- 2020-03-13 MX MX2024004377A patent/MX2024004377A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018331267A1 (en) | 2020-04-16 |
| EP4487912A3 (en) | 2025-03-26 |
| MX2024004377A (es) | 2024-04-26 |
| WO2019055225A1 (en) | 2019-03-21 |
| MX2020002852A (es) | 2020-07-22 |
| CN111093671A (zh) | 2020-05-01 |
| EP3681505C0 (en) | 2024-12-18 |
| AU2018331267B2 (en) | 2024-03-07 |
| EP3681505B1 (en) | 2024-12-18 |
| CA3073998A1 (en) | 2019-03-21 |
| IL272949B2 (en) | 2025-07-01 |
| IL272949B1 (en) | 2025-03-01 |
| IL272949A (en) | 2020-04-30 |
| JP7347743B2 (ja) | 2023-09-20 |
| JP2020533381A (ja) | 2020-11-19 |
| EP4487912A2 (en) | 2025-01-08 |
| US20210062262A1 (en) | 2021-03-04 |
| RU2020112222A (ru) | 2021-10-13 |
| US11549147B2 (en) | 2023-01-10 |
| KR20200054232A (ko) | 2020-05-19 |
| BR112020004964A2 (pt) | 2020-09-15 |
| EP3681505A1 (en) | 2020-07-22 |
| KR20250036264A (ko) | 2025-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024004377A (es) | Tratamiento mejorado de la dermatitis atopica con tradipitant. | |
| CY1123065T1 (el) | Ανασυνδυασμενα προβιοτικα βακτηριδια | |
| MX389468B (es) | Gliceril 3-hidroxibutiratos para el control de los síntomas de la migraña | |
| MX2021010460A (es) | Metodo de tratamiento con tradipitant. | |
| TWD174683S (zh) | 戒指 | |
| GEAP201914237A (en) | Heteroaryls and uses thereof | |
| GEAP202114450A (en) | Anti-tigit antibodies | |
| PE20171094A1 (es) | Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda | |
| MX373818B (es) | Composiciones de apilimod y métodos para usar las mismas. | |
| CL2016000326A1 (es) | Composiciones y método para tratar condiciones asociadas con el complemento | |
| MX2015011281A (es) | Composiciones de inh-c1 y metodos para la prevencion y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa. | |
| MX395060B (es) | Sistemas y métodos de control adecuados para el uso con sistemas y métodos de producción de energía. | |
| TWD171584S (zh) | 自動出入閘門 | |
| MX2018007123A (es) | Control remoto para el control de aparatos mediante la desviacion de la señal de realimentacion del control nativo al control remoto y metodos para el mismo. | |
| AR106133A1 (es) | Métodos para el tratamiento de la epilepsia | |
| PL3446187T3 (pl) | Sposób eksploatacji instalacji wytwórczej i instalacja wytwórcza | |
| MX386150B (es) | Tasimelteon para tratar el síndrome de smith-magenis. | |
| MX2016016664A (es) | Metodos para tratar condiciones con anticuerpos que enlazan al receptor de factor 1 estimulador de colonias (csf1r). | |
| CL2016000672A1 (es) | Bacteria aislada del género streptomyces | |
| MX2019002673A (es) | Composiciones y metodos para tratar demencia. | |
| MX2017002277A (es) | Anticuerpos que potencian el factor h y sus usos. | |
| MX385652B (es) | Composicion heterofasica. | |
| TWD179337S (zh) | 管配件 | |
| TWD180363S (zh) | 水龍頭 | |
| MX376367B (es) | Activacion del factor x. |